Company History

Mayne Pharma Pills in capsule

1980s

Salisbury site acquired in 1983 by F H Faulding & Co Limited.
Development of delayed-release doxycycline capsules (DORYX®).
Development of enteric coated aspirin (ASTRIX®).
WF Scammell Research Centre opened at Salisbury.

1990s

Development of taste-masking technology (CLEANTASTE®).
Development of sustained-release morphine (KADIAN® / KAPANOL®).

2000s

Development of improved bioavailability technology (SUBA™).
Development of pellet-in-a-tablet technology (DORYX®).
Development of LOZANOC®/TOLSURA® improved formulation of itraconazole.
Mayne Pharma LAB

2010s

Mayne Pharma acquires Metrics, Inc. – CDMO with niche generic product portfolio and pipeline.
Acquired DORYX® brand and related assets in the US from Actavis.
Mayne Pharma acquires US portfolio of products from Teva and Allergan in the US.
Mayne Pharma acquires US foam dermatology products from GSK – FABIOR® and SORILUX®.
Licensing of NEXTSTELLIS® from Estetra/Mithra
Female looking into mirror

2020s

Launch of NEXTSTELLIS® / establishment of Women’s Health team
Sold Metrics Contract Services business to Catalent
Sold retail generics portfolio to Dr Reddy’s
Acquired license to ANNOVERA®, BIJIVA®, IMVEXXY® and pre-natal vitamins from TherapeuticsMD